Q2 2025 Talphera Inc Earnings Call Transcript
Key Points
- Talphera Inc (TLPH) has successfully accelerated the enrollment rate for the NEPHRO study, doubling the number of enrolled patients since May.
- The restructuring of the NEPHRO study, including reducing the study size and changing the target profile of clinical sites, has proven effective.
- The company has received positive feedback from institutions eager to have nafamostat available, indicating strong potential market demand.
- Talphera Inc (TLPH) has reduced its expected 2025 cash operating expenses to $16 million to $17 million, down from the previous range of $17 million to $19 million.
- The company has a clear regulatory path with breakthrough designation from the FDA, minimizing regulatory risk for the nafamostat program.
- The company faces ongoing supply chain issues with heparin and citrate, which are critical for CRRT, creating uncertainty in the market.
- There is a dependency on achieving stock price milestones for additional financing, which may pose a risk if the stock does not reach the required levels.
- The initial clinical sites inherited from the previous owner were not suitable for the NEPHRO study, causing delays in patient enrollment.
- The company needs to secure additional capital to reach the PMA filing, indicating potential financial constraints.
- Despite progress, there is still a risk of not meeting the enrollment target by year-end if new sites do not ramp up as expected.
Welcome to the Talphera second-quarter 2025 financial results conference call. This call is being webcast live via the Events page of the Investor section of Talphera's website at www.talphera.com. You may listen to a replay of this webcast by going to the Investor section of Talphera's website.
I would now like to turn the call over to Raffi Asadorian, Talphera's Chief Financial Officer.
Thanks, Andrew, and thank you for joining us on the call today. Today, we announced our second-quarter 2025 financial results and associated business updates in a press release. With me today are Vince Angotti, our Chief Executive Officer; and Dr. Shakil Aslam, Talphera's Chief Medical Officer.
Before we begin, I want to remind listeners that during this call, we will likely make forward-looking statements within the meaning of the federal securities laws. These forward-looking statements involve risks and uncertainties regarding the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
